

Date: 14/11/2024

To  
BSE Limited,  
Dept. of Corporate Services,  
Floor 25, PJ Towers,  
Dalal Street, Mumbai- 400001

Dear Sir/Madam,

Scrip Code: 526445

Sub: Outcome of Board Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements} Regulations, 2015

With reference to our intimation letter dated November 11, 2024 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that at the meeting of Board of Directors held today i.e., on Thursday, November 14, 2024, the Directors have inter-alia, approved the following:

- i. Unaudited Financial Results (Standalone and Consolidated) with the Limited Review Report for the quarter and half year ended September 30, 2024 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements} Regulations, 2015. The statutory auditors have reviewed the financial results and given unmodified opinion. (Results are provided as Annexure). The necessary arrangements are in place to publish the unaudited financial results in the newspapers. The said financial results will also be available on company's website [www.indrayani.com](http://www.indrayani.com) and also on BSE website [www.bseindia.com](http://www.bseindia.com).
- ii. The Board has considered the issue of fully paid up equity shares by way of a rights issue to the existing shareholders of the Company in accordance with the provisions of Companies Act, 2013 and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and other applicable laws for an amount not exceeding Rs.49.90 Crores (Rupees Forty Nine crores Ninety Lakhs).
- iii. Further, the Board has constituted a Rights Issue Committee and authorized its members to decide on the terms and conditions of the Issue, including but not limited to, the final Issue size/amount, rights entitlement ratio, the issue price, record date, timing of the Rights Issue, approval of draft letter of offer; appointment of intermediaries, if required; allotment of shares and other related matters.

The meeting commenced at 03:00 p.m. and concluded at 11:40 p.m.

This is for your information and records.

Thanking You,

Yours Faithfully,

For Indrayani Biotech Limited  
**SANTHANAK** Digitally signed by  
**RISHNAN V** SANTHANAKRISHN  
AN V

V Santhanakrishnan  
Company Secretary and Compliance Officer

Encl.: as above



**Limited Review Report on consolidated unaudited quarterly to date financial results of the company Pursuant to the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015**

To  
The Board of Directors  
**Indrayani Biotech Limited**

We have reviewed the accompanying Statement of Consolidated Financial Results of Indrayani Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income / loss of its associates for the quarter ended **30<sup>th</sup> September, 2024** and for the period from 1<sup>st</sup> July 2024 to 30<sup>th</sup> September 2024 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30<sup>th</sup> September, 2023 and corresponding period from 1<sup>st</sup> July 2023 to 30<sup>th</sup> September 2023 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to audit/review.


This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our review of such consolidated financial statements.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the entities mentioned in the Annexure – I, is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended;

Based on our review conducted and procedures performed as stated in paragraph above and based on the consideration of the reports of the management referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)



SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai- 600 017.

Telefax: 2814 4763/64/65/66 Email: audit@venkateshandco.com



**VENKATESH & CO**  
Chartered Accountants

Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the financial statement / financial information of **6 Subsidiaries and 3 step down subsidiaries** included in the consolidated unaudited financial results, whose interim financial information for the Period ended 30<sup>th</sup> September, 2024 reflects total revenues of ₹ **1,314.81 Lakhs**, total comprehensive profit / (loss) of ₹ **(17.35 Lakhs)** for the period ended on that date as considered in the consolidated financial results.

This financial information have been reviewed by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the Management and the procedures performed by us as stated in paragraph mentioned above.

**for Venkatesh & Co**

Chartered Accountants

FRN : 004636S

*Hrishikesh D*  
**CA Hrishikesh D**

Partner

M No : 272865



UDIN: **24272865BKNPVE5679**

Chennai, 14<sup>th</sup> November 2024



**Annexure I to the Audit Report**

List of subsidiaries, associates and joint ventures included in the consolidated Quarterly Unaudited financial results:

S. No.	Name of the entity	Relationship
1	IBL Health Care Limited	Subsidiary
2	HSL Agri Solutions Limited	Subsidiary
3	HSL Prime Properties Private Limited	Subsidiary
4	Healthway India Private Limited	Step Down Subsidiary
5	IBL Thiruvannamalai LLP	Step Down Subsidiary
6	Dindigul Farm Product Limited*	Subsidiary
7	Matrix Boilers Private Limited	Subsidiary
8	IBL Investments Limited	Subsidiary
9	IBL Social Foundation	Subsidiary
10	Kniss Laboratories Private Limited	Step Down Subsidiary

**\*Consolidation Comprises of Financial results of Dindigul Farm Product Limited by the virtue of Control established over Board of Directors and decisions of management.**



## M/s. INDRAYANI BIOTECH LIMITED

CIN : L40100TN1992PLC129301

BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032

Unaudited Consolidated Balance sheet as at 30-09-2024

Particulars	As at	As at
	30 Sep 2024	31 Mar 2024
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	3,722.02	3,907.87
Capital Work in Progress	2,369.27	2,029.84
Goodwill	2,334.73	2,334.73
Other Intangible Assets		
Financial assets	22.57	22.33
(i) Investments	481.89	467.93
(ii) Other financial assets	136.06	135.55
Deffered Tax Assets	106.17	106.68
Non-current tax assets		-
Other Non Current Assets		
<b>Total non-current assets</b>	<b>9,172.71</b>	<b>9,004.93</b>
<b>Current assets</b>	4,076.02	4,235.05
Inventories		
Financial assets	3,972.73	3,952.89
(i) Trade receivables	312.54	58.21
(ii) Cash and cash equivalents	692.12	684.78
(iii) Loans	4,444.01	2,966.97
(iv) Other Financial Assets	176.77	136.05
Current Tax Assets (Net)	2,321.42	2,463.65
Other current assets		
<b>Total current assets</b>	<b>15,995.61</b>	<b>14,497.60</b>
<b>TOTAL ASSETS</b>	<b>15,995.61</b>	<b>14,497.60</b>
	<b>25,168.33</b>	<b>23,502.54</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	4,553.63	4,553.63
Other equity	2,912.38	2,167.50
Non Controlling Interests	3,297.12	905.37
<b>Total equity</b>	<b>10,763.13</b>	<b>7,626.50</b>
<b>Non-current liabilities</b>		
Financial liabilities	4,890.83	6,659.6
(i) Borrowings	397.99	406.7
(ii) Lease Liabilities	102.38	102.3
Deffered Tax liabilities		
<b>Total non-current liabilities</b>	<b>5,391.20</b>	<b>7,168.7</b>
<b>Current liabilities</b>		
Financial liabilities	4,679.18	4,106.7
(i) Borrowings	79.36	79.
(ii) Lease Liabilities		
(iii) Trade payables		
Total outstanding dues to micro enterprises and small enterprises; and	3,137.80	3,739.
Total outstanding dues of creditors other than micro enterprises and small enterprises		
(iv) Other Financial Liabilities	221.50	16
Other current liabilities	364.05	276
Provision	532.11	488
<b>Total current liabilities</b>	<b>9,014.00</b>	<b>8,707</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>25,168.33</b>	<b>23,502.</b>

For INDRAYANI BIOTECH LIMITED

*G. Swaminathan*  
Director

**M/s. INDRAYANI BIOTECH LIMITED**

CIN : L40100TN1992PLC129301

#32 & 33 Block: I, 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.

**STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30th September, 2024**

Rs in Lakhs

S No	Particulars	CONSOLIDATED					
		Quarter Ended			Half Year Ended		Year Ended
		30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	3,081.31	3,152.78	4,044.02	6,234.09	8,275.27	16,622.56
II	Other Income	30.13	4.43	9.06	34.56	9.92	121.49
III	<b>Total Income</b>	<b>3,111.44</b>	<b>3,157.21</b>	<b>4,053.08</b>	<b>6,268.65</b>	<b>8,285.19</b>	<b>16,744.06</b>
IV	<b>Expenses</b>						
	Cost of Materials consumed	1,709.42	1,667.00	2,452.00	3,376.42	5,267.54	9,713.25
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-222.25	91.33		-130.92		
	Employee Benefit Expense	513.94	571.95	510.98	1,085.89	1,049.50	2,392.94
	Finance Cost	141.60	224.87	93.44	366.47	296.24	988.25
	Depreciation and amortization expense	279.46	82.74	90.82	362.20	180.67	380.06
	Other expenses	569.44	424.85	351.58	994.29	975.31	2,172.11
	<b>Total Expenses</b>	<b>2,991.61</b>	<b>3,062.75</b>	<b>3,498.83</b>	<b>6,054.36</b>	<b>7,769.27</b>	<b>15,646.62</b>
V	Profit / (loss) before exceptional items and tax	<b>119.84</b>	<b>94.46</b>	<b>554.25</b>	<b>214.30</b>	<b>515.92</b>	<b>1,097.44</b>
VI	Exceptional Items						
VII	Add : Share of profit In Associates	119.84	94.46	554.25	214.30	515.92	1,097.44
VIII	Profit / (loss) before tax						
		-1.85	9.45	-	7.60	-	61.85
IX	Current Tax Expense						-6.66
X	Deferred Tax Expense						
XI	Profit (Loss) for the period from continuing operations (VII-VIII)	<b>121.69</b>	<b>85.01</b>	<b>554.25</b>	<b>206.70</b>	<b>515.92</b>	<b>1,042.25</b>
XII	Profit (Loss) for the period from discontinued operations						
XIII	Profit (Loss) for the period (VII-VIII)						
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive income for the period attributable to	<b>121.69</b>	<b>85.01</b>	<b>554.25</b>	<b>206.70</b>	<b>515.92</b>	<b>1,042.25</b>
XVI	Comprehensive income for the period attributable to owners of parent	<b>61.20</b>	43.90	313.04	105.10	291.84	636.49
XVII	Total comprehensive income for the period attributable to Non-controlling Interests	<b>60.48</b>	41.11	247.45	101.59	224.08	405.79
XVIII	Paid-up equity share capital (Face value Rs.10 each)	<b>4,553.63</b>	<b>4,553.63</b>	<b>3,422.72</b>	<b>4,553.63</b>	<b>3,422.72</b>	<b>4,553.63</b>
XX	Earnings Per Share:						
	(1) Basic *not annualised	0.13*	0.01*	0.89*	0.02*	0.83*	1.40
	(2) Diluted *not annualised	0.13*	0.01*	0.96*	0.02*	0.83*	1.40

**Notes:**

1. The above Standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors Directors at their meeting held on 14th November 2024 and have been subjected to review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

2. The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com).

3. The figures for the quarter ended 30 September 2024 are the balancing figures between the audited figures in respect of the financial year ended 31 March 2024 and published year to date figures for six months ended 30 September 2024, which were subjected to limited review by the statutory auditors.

4. Previous period figures have been regrouped wherever necessary.

5. There is no investor complaint received during the quarter.

for and on behalf of the Board of Directors of  
Indrayani Biotech Limited

G.Swaminathan  
Whole time Director  
DIN: 02481041

Date:14.11.2024  
Place: Chennai

M/s. INDRAYANI BIOTECH LIMITED  
BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY,  
CHENNAI, 600032

CIN : L40100TN1992PLC129301

Unaudited Consolidated Statement of Cash Flows for the year ended 30th Sep 2024

Particulars	As on 30-Sep-24	As on 31-Mar-24
<b>Cash Flows From Operating Activities:-</b>		
Net Profit after Taxation	206.69	1,042.27
<b>Adjustment for Non cash items</b>		
Add : Impairment of Fixed Assets	-	-
Add : Depreciation	362.20	380.53
Less : Interest Income Notional (As per Ind AS 109)	(2.17)	(4.56)
Add : Notional Rent as per IND AS		
Add : Interest Expenses Notional as per Applicable IndAS	30.15	30.12
Less: Share of profit of Associates		(0.49)
Other Comprehensive Income		
<b>Adjustment for Non Operating activities</b>		
Add : Interest Paid	366.47	958.13
Less : Interest income	-	-
	<b>963.34</b>	<b>2,406.00</b>
<b>Cash Flow Before Working Capital changes:-</b>		
Decrease (Increase) in Inventories	159.03	(3,013.66)
Decrease (Increase) in Trade receivables	(19.84)	(955.73)
Decrease (Increase) in current assets	(40.72)	(25.65)
Decrease (Increase) in Other Financial Assets	(1,491.00)	(2,001.21)
Decrease (Increase) in other current assets	142.23	(546.37)
(Decrease) Increase in Short term borrowings	572.48	769.22
(Decrease) Increase in Financial Liabilities	204.63	(291.31)
(Decrease) Increase in Trade payables	(601.24)	1,465.21
(Decrease) Increase in Other Current liabilities	87.17	(489.82)
(Decrease) Increase in Loans	(7.34)	(448.19)
(Decrease) Increase in Provisions	43.71	96.10
<b>Cash Flow Before Tax and Extraordinary Items:-</b>		
Income Taxes Paid	-	-
	<b>12.45</b>	<b>(3,035.41)</b>
<b>Net Cash Flow From Operating Activities</b>		
<b>Cash Flow from Investing Activities:-</b>		
Less : Purchase of Capital Assets	(404.86)	(1,630.15)
Less : Increase / Decrease in Advances for Capital Expenditure	(339.43)	(18.58)
Add : Goodwill on Consolidation		-
Less : Purchase of Investments		-
Less : Sale of Capital Assets		6.62
Add: Interest Income		-
Decrease (Increase) in Loans and advances & Other assets	21.26	8.21
	<b>(723.03)</b>	<b>(1,633.90)</b>
<b>Net Cash flow used in Investing Activities</b>		
<b>Cash Flow from Financing Activities:-</b>		
Increase in Borrowings		3,722.61
Increase in Lease Liabilities		-
Interest Income Notional (As per Ind AS 109)	2.17	4.56
Increase in Share Capital	645.00	463.29
Repayment of Lease Liabilities	(21.46)	(84.83)
Increase in Non Controlling interest	3,041.36	1,578.83
Issue Expenses Paid	(566.87)	(272.36)
Interest expense	(366.47)	(988.25)
Decrease in borrowings	(1,768.82)	-
	<b>964.91</b>	<b>4,423.85</b>
<b>Net Cash Flow From Financing Activities</b>		
<b>Net Increase/(Decrease) in Cash and Cash Equivalents:-</b>		
(Opening Balance)	58.21	303.67
Net Cash Flow during the year	254.33	(245.46)
<b>(Closing Balance)</b>	<b>312.54</b>	<b>58.21</b>

For INDRAYANI BIOTECH LIMITED

  
G. SWAMINATHAN  
Director



**VENKATESH & CO**  
Chartered Accountants

**Limited Review Report on Quarterly Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
The Board of Directors,  
**Indrayani Biotech Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter ended 30<sup>th</sup> September 2024. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **Venkatesh & Co**  
Chartered Accountants  
FRN : 0046365

  
CA Hrishikesh D

Partner

M No : 272865

UDIN: **24272865BKNPVD3610**

Chennai, 14<sup>th</sup> November 2024





Unaudited Standalone Balance sheet as on 30-09-2024

Particulars	As at 30 September 2024	As at 31 Mar 2024
<b>ASSETS</b>		
<b>NON-CURRENT ASSETS</b>		
Property, plant and equipment	1,739.76	1,782.42
Capital Work in Progress	1,809.07	1,802.91
Goodwill	383.53	383.53
<b>Financial assets</b>	955.81	955.81
(i) Investments	431.10	419.52
(ii) Other financial assets	106.17	106.17
<b>Non-current tax assets</b>	-	-
<b>Other Non Current Assets</b>		
<b>Total non-current assets</b>	<b>5,425.44</b>	<b>5,450.36</b>
<b>CURRENT ASSETS</b>		
Inventories	188.50	192.32
<b>Financial assets</b>	1,690.39	1,759.63
(i) Trade receivables	109.85	26.29
(ii) Cash and cash equivalents	5,196.72	3,921.59
(iii) Loans	170.56	339.90
(iv) Other Financial Assets	176.77	136.05
<b>Current Tax Assets (Net)</b>	707.56	774.69
<b>Other current assets</b>		
<b>Total current assets</b>	<b>8,240.35</b>	<b>7,150.47</b>
<b>TOTAL ASSETS</b>	<b>13,665.79</b>	<b>12,600.83</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity share capital	4,553.63	4,553.63
Other equity	857.50	897.90
<b>Total equity</b>	<b>5,411.13</b>	<b>5,451.53</b>
<b>NON-CURRENT LIABILITIES</b>		
<b>Financial liabilities</b>	1,416.99	1,487.95
(i) Borrowings	397.99	406.70
(ii) Lease Liabilities	102.38	102.38
Deffered Tax liabilities		
<b>Total non-current liabilities</b>	<b>1,917.36</b>	<b>1,997.03</b>
<b>CURRENT LIABILITIES</b>		
<b>Financial liabilities</b>	4,956.81	4,371.83
(i) Borrowings	79.36	79.36
(ii) Lease Liabilities		
(ii) Trade payables		
Total outstanding dues to micro enterprises and small enter	-	-
Total outstanding dues of creditors other than micro	569.76	272.34
enterprises and small enterprises	221.50	-
(ii) Other Financial Liabilities	205.29	138.36
<b>Other current liabilities</b>	304.58	290.38
<b>Provision</b>		
<b>Total current liabilities</b>	<b>6,337.30</b>	<b>5,152.27</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>13,665.79</b>	<b>12,600.83</b>

For INDRAYANI BIOTECH LIMITED

  
 G. SWAMINATHAN Director

**M/s. INDRAYANI BIOTECH LIMITED**

CIN : L40100TN1992PLC129301

#32 & 33 Block: I, 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.

**STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30th September, 2024**

Rs in Lakhs


S No	Particulars	STANDALONE					
		Quarter Ended			Half Year Ended		Year Ended
		30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
I	Revenue from Operations	950.69	1,079.09	1,601.33	2,029.78	3,283.19	6,232.34
II	Other Income	89.38	102.60	8.59	191.98	9.13	361.88
III	<b>Total Income</b>	<b>1,040.07</b>	<b>1,181.69</b>	<b>1,609.92</b>	<b>2,221.76</b>	<b>3,292.32</b>	<b>6,594.22</b>
IV	<b>Expenses</b>						
	Cost of Materials consumed	379.96	484.52	1,028.99	864.48	1,980.98	3,515.38
	Employee Benefit Expense	320.38	403.58	390.57	723.96	752.10	1,569.08
	Finance Cost	188.52	151.63	61.71	340.15	157.54	482.76
	Depreciation and amortization expense	31.76	31.98	36.51	63.74	72.59	144.76
	Other expenses	106.29	92.93	51.62	199.22	216.95	581.31
	<b>Total Expenses</b>	<b>1,026.91</b>	<b>1,164.64</b>	<b>1,569.41</b>	<b>2,191.55</b>	<b>3,180.16</b>	<b>6,293.29</b>
V	Profit / (loss) before exceptional items and tax	<b>13.16</b>	<b>17.05</b>	<b>40.50</b>	<b>30.21</b>	<b>112.16</b>	<b>300.91</b>
VI	Exceptional Items						
	Add : Share of profit In Associates	13.16	17.05	40.50	30.21	112.16	300.91
VII	Profit / (loss) before tax						
		3.27	4.33	-	7.60	-	54.17
VIII	Current Tax Expense	-	-	-	-	-	101.00
IX	Deferred Tax Expense						
X	Profit (Loss) for the period from continuing operations (VII-VIII)	<b>9.89</b>	<b>12.72</b>	<b>40.50</b>	<b>22.61</b>	<b>112.16</b>	<b>145.74</b>
X	Profit (Loss) for the period from discontinued operations						
XI	Profit (Loss) for the period (VII-VIII)						
XII	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XIII	Total Comprehensive Income for the period (XII+XI)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	<b>9.89</b>	<b>12.72</b>	<b>40.50</b>	<b>22.61</b>	<b>112.16</b>	<b>145.74</b>
XIV	Paid-up equity share capital (Face value Rs.10 each)	<b>4,553.63</b>	<b>4,553.63</b>	<b>3,422.72</b>	<b>4,553.63</b>	<b>3,422.72</b>	<b>4,553.63</b>
XX	Earnings Per Share:						
	(1) Basic	0.02	0.03	0.12	0.05	0.33	0.37
	(2) Diluted	0.02	0.03	0.11	0.05	0.31	0.37

**Notes:**

- The above Standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors. The above Directors at their meeting held on 14th November 2024 and have been subjected to review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com).
- The figures for the quarter ended 30 September 2024 are the balancing figures between the audited figures in respect of the financial year ended 31 March 2024 and published year to date figures for six months ended 30 September 2024, which were subjected to limited review by the statutory auditors.
- Previous period figures have been regrouped wherever necessary.
- There is no investor complaint received during the quarter.

Date:14.11.2024  
Place: Chennai

**for and on behalf of the Board of Directors of  
Indrayani Biotech Limited**

  
 G Swaminathan  
 Whole time Director  
 DIN: 02481041

M/s. INDRAYANI BIOTECH LIMITED  
CIN : L40100TN1992PLC129301

BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI,  
600032

Particulars	Rs. In Lakhs	
	As on 30-Sep-2024	As on 31-Mar-24
<b>Unaudited Standalone Cash Flow Statement for the half year ended 30-09-2024</b>		
<b>Cash Flows From Operating Activities:-</b>		
Net Profit after Taxation	30.21	300.91
<b>Adjustment for Non cash items</b>		
Add : Impairment/ Write off of Property Plant and Equipment and Capital Work in Progress	63.74	144.76
Add : Depreciation	(2.17)	(4.18)
Less : Interest Income Notional (As per Ind AS 109)		-
Add : Notional Rent as per IND AS	30.15	30.12
Add: Interest Expenses Notional as per applicable IndAS	310.00	452.64
<b>Adjustment for Non Operating activities</b>		
Add : Interest Paid ( Including Interest on Lease Liabilities)	-	-
Less : Interest income		
<b>Cash Flow Before Working Capital changes:-</b>	<b>431.93</b>	<b>924.25</b>
Decrease (Increase) in Inventories	3.82	(5.87)
Decrease (Increase) in Trade receivables	69.24	(136.93)
Decrease (Increase) in Current Tax Assets	(40.72)	(25.65)
Decrease (Increase) in Other Financial Assets	169.34	61.46
Decrease (Increase) in other current assets	67.13	(87.84)
(Decrease) Increase in Short term borrowings	584.98	1,820.63
(Decrease) Increase in Financial liabilities	221.50	(228.35)
(Decrease) Increase in Trade payables	297.42	115.90
(Decrease) Increase in Other Current liabilities	66.93	67.32
(Decrease) Increase in Provisions	14.20	103.98
	-	-
<b>Cash Flow Before Tax and Extraordinary Items:-</b>	<b>1,885.78</b>	<b>2,608.91</b>
Income Taxes Paid		
<b>Net Cash Flow From Operating Activities</b>		
<b>Cash Flow from Investing Activities:-</b>		
Less : Purchase of Capital Assets	(27.19)	(634.37)
Less : Purchase of Investments	-	(157.19)
Add : Rental Receipts	-	-
Add : Amount of Interest Received	-	-
Less : Sale of Capital Assets	-	-
Decrease (Increase) in Loans and advances & Other assets	(19.18)	65.68
	<b>(46.37)</b>	<b>(725.88)</b>
<b>Net Cash flow used in Investing Activities</b>		
<b>Cash Flow from Financing Activities:-</b>		
Increase in Borrowings	(70.96)	511.94
Interest Income Notional (As per Ind AS 109)	2.17	4.18
Increase in Share capital	-	205.91
Issue of Share Warrant	-	-
Interest expense( Including Interest on Lease Liabilities)	(340.15)	(482.76)
Repayment of Lease Liabilities	(8.71)	(84.83)
Loan to Group Companies	(1,275.22)	(2,058.12)
Security Premium Received	(63.00)	257.38
Issue Expenses Paid	-	(272.36)
Decrease in borrowings		
<b>Net Cash Flow From Financing Activities</b>	<b>(1,755.85)</b>	<b>(1,918.64)</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents:-</b>		
(Opening Balance)	26.29	61.90
Net Cash Flow during the year	83.56	(35.61)
<b>(Closing Balance)</b>	<b>109.85</b>	<b>26.29</b>

For INDRAYANI BIOTECH LIMITED

*G. Swaminathan*  
Director